Functional cure of chronic hepatitis B is not a dream
- VernacularTitle:慢性乙型肝炎功能性治愈不是梦
- Author:
Hui ZHUANG
1
Author Information
- Publication Type:Journal Article
- Keywords: Hepatitis B， Chronic; Hepatitis B Virus; Functional Cure; Complete Cure; Antiviral Agents
- From: Journal of Clinical Hepatology 2025;41(1):2-6
- CountryChina
- Language:Chinese
- Abstract: Functional cure of chronic hepatitis B （CHB） is defined as HBsAg<0.05 IU/mL and serum HBV DNA<10 IU/mL for at least 24 weeks after discontinuation of antiviral therapy. This requires suppression of HBV replication and reduction of viral antigen production， as well as restoration of immune response to HBV infection. About 30% — 50% of highly selected CHB patients treated with nucleos（t）ide analogues can achieve functional cure after add-on therapy or monotherapy with pegylated interferon-α or a finite course of treatment with nucleos（t）ide analogues among patients with HBsAg<100 IU/mL. At present， clinical trials are being conducted for more than 40 types of novel anti-HBV drugs and immunomodulators. The combination of drugs that inhibit viral replication， reduce antigen burden， and restore immune response to HBV infection may be an ideal strategy to achieve the functional cure of CHB. However， further studies are needed to determine the optimal drug combination， the timing and sequence of medication， and the duration of treatment.
